Matrix metalloproteinase 9 and cellular fibronectin plasma concentrations are predictors of the composite endpoint of length of stay and death in the intensive care unit after severe traumatic brain injury

Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine

Volumn 20, Issue , 2012, Pages

  Copin, Jean Christophe ^a,b,d   Rebetez, Marie My Lien ^b   Turck, Natacha ^c   Robin, Xavier ^c   Sanchez, Jean Charles ^c   Schaller, Karl ^c   Gasche, Yvan ^a,b   Walder, Bernhard ^b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^d Center Médical Universitaire   (Switzerland)

Author keywords

Head injury; Outcome; Plasmatic biomarker; Prediction

Indexed keywords

BIOLOGICAL MARKER; FIBRONECTIN; GELATINASE B;

ADULT; ARTICLE; BLOOD; BRAIN INJURY; CONFIDENCE INTERVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FORECASTING; GLASGOW COMA SCALE; GLASGOW OUTCOME SCALE; HUMAN; INJURY SCALE; INTENSIVE CARE UNIT; LENGTH OF STAY; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; RISK; STATISTICAL MODEL; SURVIVOR; SWITZERLAND;

ADULT; BIOLOGICAL MARKERS; BRAIN INJURIES; CONFIDENCE INTERVALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRONECTINS; FORECASTING; GLASGOW COMA SCALE; GLASGOW OUTCOME SCALE; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; LOGISTIC MODELS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; ODDS RATIO; SURVIVORS; SWITZERLAND; TRAUMA SEVERITY INDICES;

MLCS; MLOWN;

EID: 84871166997     PISSN: None     EISSN: 17577241     Source Type: Journal    
DOI: 10.1186/1757-7241-20-83     Document Type: Article

References (47)

1. Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jonsson B. The economic cost of brain disorders in Europe. Eur J Neurol 2012, 19:155-162. 10.1111/j.1468-1331.2011.03590.x, 22175760.
2. van Velzen JM, van Bennekom CA, Edelaar MJ, Sluiter JK, Frings-Dresen MH. How many people return to work after acquired brain injury?: a systematic review. Brain Inj 2009, 23:473-488. 10.1080/02699050902970737, 19484621.
3. Bouillon B, Raum M, Fach H, Buchheister B, Lefering R, Menzel J, Klug N. The incidence and outcome of severe brain trauma - Design and first results of an epidemiological study in an urban area. Restor Neurol Neurosci 1999, 14:85-92.
4. Masson F, Thicoipe M, Aye P, Mokni T, Senjean P, Schmitt V, Dessalles PH, Cazaugade M, Labadens P, Injur AGSB. Epidemiology of severe brain injuries: a prospective population-based study. J Trauma 2001, 51:481-489. 10.1097/00005373-200109000-00010, 11535895.
5. Andelic N, Anke A, Skandsen T, Sigurdardottir S, Sandhaug M, Ader T, Roe C. Incidence of hospital-admitted severe traumatic brain injury and in-hospital fatality in Norway: a national cohort study. Neuroepidemiology 2012, 38:259-267. 10.1159/000338032, 22678449.
6. Andriessen TM, Horn J, Franschman G, van der Naalt J, Haitsma I, Jacobs B, Steyerberg EW, Vos PE. Epidemiology, severity classification, and outcome of moderate and severe traumatic brain injury: a prospective multicenter study. J Neurotrauma 2011, 28:2019-2031. 10.1089/neu.2011.2034, 21787177.
7. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997, 349:1269-1276. 10.1016/S0140-6736(96)07493-4, 9142060.
8. von Elm E, Osterwalder JJ, Graber C, Schoettker P, Stocker R, Zangger P, Vuadens P, Egger M, Walder B. Severe traumatic brain injury in Switzerland - feasibility and first results of a cohort study. Swiss Med Wkly 2008, 138:327-334.
9. Roozenbeek B, Chiu YL, Lingsma HF, Gerber LM, Steyerberg EW, Ghajar J, Maas AI. Predicting 14-day mortality after severe traumatic brain injury: application of the IMPACT models in the brain trauma foundation TBI-trac(R) New York State database. J Neurotrauma 2012, 29:1306-1312. 10.1089/neu.2011.1988, 22150207.
10. Zuercher M, Ummenhofer W, Baltussen A, Walder B. The use of Glasgow Coma Scale in injury assessment: a critical review. Brain Inj 2009, 23:371-384. 10.1080/02699050902926267, 19408162.
11. Bohmer AE, Oses JP, Schmidt AP, Peron CS, Krebs CL, Oppitz PP, D'Avila TT, Souza DO, Portela LV, Stefani MA. Neuron-specific enolase, S100B, and glial fibrillary acidic protein levels as outcome predictors in patients with severe traumatic brain injury. Neurosurgery 2011, 68:1624-1630. discussion 1630-1621, 10.1227/NEU.0b013e318214a81f, 21368691.
12. Dalla Libera AL, Regner A, de Paoli J, Centenaro L, Martins TT, Simon D. IL-6 polymorphism associated with fatal outcome in patients with severe traumatic brain injury. Brain Inj 2011, 25:365-369. 10.3109/02699052.2011.556107, 21314275.
13. Hergenroeder GW, Moore AN, McCoy JP, Samsel L, Ward NH, Clifton GL, Dash PK. Serum IL-6: a candidate biomarker for intracranial pressure elevation following isolated traumatic brain injury. J Neuroinflammation 2010, 7:19. 10.1186/1742-2094-7-19, 2853529, 20222971.
14. Lin Z, Han M, Li H, Luo H, Zhang Y, Luo W. Soluble vascular adhesion protein-1: decreased activity in the plasma of trauma victims and predictive marker for severity of traumatic brain injury. Clin Chim Acta 2011, 412:1678-1682. 10.1016/j.cca.2011.05.031, 21645499.
15. McKeating EG, Andrews PJ, Mascia L. The relationship of soluble adhesion molecule concentrations in systemic and jugular venous serum to injury severity and outcome after traumatic brain injury. Anesth Analg 1998, 86:759-765.
16. Mondello S, Gabrielli A, Catani S, D'Ippolito M, Jeromin A, Ciaramella A, Bossu P, Schmid K, Tortella F, Wang KK, et al. Increased levels of serum MAP-2 at 6-months correlate with improved outcome in survivors of severe traumatic brain injury. Brain Inj 2012, 26:1629-1635. 10.3109/02699052.2012.700083, 22794497.
17. Mondello S, Linnet A, Buki A, Robicsek S, Gabrielli A, Tepas J, Papa L, Brophy GM, Tortella F, Hayes RL, Wang KK. Clinical utility of serum levels of ubiquitin C-terminal hydrolase as a biomarker for severe traumatic brain injury. Neurosurgery 2012, 70:666-675.
18. Sen J, Belli A. S100B in neuropathologic states: the CRP of the brain?. J Neurosci Res 2007, 85:1373-1380. 10.1002/jnr.21211, 17348038.
19. Vos PE, Jacobs B, Andriessen TM, Lamers KJ, Borm GF, Beems T, Edwards M, Rosmalen CF, Vissers JL. GFAP and S100B are biomarkers of traumatic brain injury: an observational cohort study. Neurology 2010, 75:1786-1793. 10.1212/WNL.0b013e3181fd62d2, 21079180.
20. Gasche Y, Soccal PM, Kanemitsu M, Copin JC. Matrix metalloproteinases and diseases of the central nervous system with a special emphasis on ischemic brain. Front Biosci 2006, 11:1289-1301. 10.2741/1883, 16368516.
21. Gidday JM, Gasche YG, Copin JC, Shah AR, Perez RS, Shapiro SD, Chan PH, Park TS. Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am J Physiol Heart Circ Physiol 2005, 289:H558-568. 10.1152/ajpheart.01275.2004, 15764676.
22. Copin JC, Merlani P, Sugawara T, Chan PH, Gasche Y. Delayed matrix metalloproteinase inhibition reduces intracerebral hemorrhage after embolic stroke in rats. Exp Neurol 2008, 213:196-201. 10.1016/j.expneurol.2008.05.022, 2557056, 18590727.
23. Rosell A, Cuadrado E, Ortega-Aznar A, Hernandez-Guillamon M, Lo EH, Montaner J. MMP-9-Positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke 2008, 39:1121-1126. 10.1161/STROKEAHA.107.500868, 18323498.
24. Jia F, Pan YH, Mao Q, Liang YM, Jiang JY. Matrix metalloproteinase-9 expression and protein levels after fluid percussion injury in rats: the effect of injury severity and brain temperature. J Neurotrauma 2010, 27:1059-1068. 10.1089/neu.2009.1067, 20233042.
25. Lescot T, Fulla-Oller L, Palmier B, Po C, Beziaud T, Puybasset L, Plotkine M, Gillet B, Meric P, Marchand-Leroux C. Effect of Acute Poly(ADP-Ribose) Polymerase Inhibition by 3-AB on Blood-brain Barrier Permeability and Edema Formation after Focal Traumatic Brain Injury in Rats. J Neurotrauma 2010, 27:1069-1079. 10.1089/neu.2009.1188, 20380552.
26. Truettner JS, Alonso OF, Dalton Dietrich W. Influence of therapeutic hypothermia on matrix metalloproteinase activity after traumatic brain injury in rats. J Cereb Blood Flow Metab 2005, 25:1505-1516. 10.1038/sj.jcbfm.9600150, 15959464.
27. Wang XY, Jung JC, Asahi M, Chwang W, Russo L, Moskowitz MA, Dixon CE, Fini ME, Lo EH. Effects of matrix metalloproteinase-9 gene knock-out on morphological and motor outcomes after traumatic brain injury. J Neurosci 2000, 20:7037-7042.
28. Tejima E, Guo SZ, Murata Y, Arai K, Lok J, van Leyen K, Rosell A, Wang XY, Lo EH. Neuroprotective Effects of Overexpressing Tissue Inhibitor of Metalloproteinase TIMP-1. J Neurotrauma 2009, 26:1935-1941. 10.1089/neu.2009.0959, 2822804, 19469687.
29. Grossetete M, Phelps J, Arko L, Yonas H, Rosenberg GA. Elevation of matrix metalloproteinases 3 and 9 in cerebrospinal fluid and blood in patients with severe traumatic brain injury. Neurosurgery 2009, 65:702-708. 10.1227/01.NEU.0000351768.11363.48, 2764327, 19834375.
30. Suehiro E, Fujisawa H, Akimura T, Ishihara H, Kajiwara K, Kato S, Fujii M, Yamashita S, Maekawa T, Suzuki M. Increased matrix metalloproteinase-9 in blood in association with activation of interleukin-6 after traumatic brain injury: Influence of hypothermic therapy. J Neurotrauma 2004, 21:1706-1711. 10.1089/neu.2004.21.1706, 15684762.
31. Vilalta A, Sahuquillo J, Rosell A, Poca MA, Riveiro M, Montaner J. Moderate and severe traumatic brain injury induce early overexpression of systemic and brain gelatinases. Intensive Care Med 2008, 34:1384-1392. 10.1007/s00134-008-1056-1, 18350273.
32. Singh P, Carraher C, Schwarzbauer JE. Assembly of fibronectin extracellular matrix. Annu Rev Cell Dev Biol 2010, 26:397-419. 10.1146/annurev-cellbio-100109-104020, 20690820.
33. White ES, Baralle FE, Muro AF. New insights into form and function of fibronectin splice variants. J Pathol 2008, 216:1-14. 10.1002/path.2388, 18680111.
34. Astrof S, Hynes RO. Fibronectins in vascular morphogenesis. Angiogenesis 2009, 12:165-175. 10.1007/s10456-009-9136-6, 2716138, 19219555.
35. Peters JH, Loredo GA, Chen G, Maunder R, Hahn TJ, Willits NH, Hynes RO. Plasma levels of fibronectin bearing the alternatively spliced EIIIB segment are increased after major trauma. J Lab Clin Med 2003, 141:401-410. 10.1016/S0022-2143(03)00042-8, 12819638.
36. Castellanos M, Sobrino T, Millan M, Garcia M, Arenillas J, Nombela F, Brea D, Perez De La Ossa N, Serena J, Vivancos J, et al. Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke. A multicenter confirmatory study. Stroke 2007, 38:1855-1859. 10.1161/STROKEAHA.106.481556, 17478737.
37. American Association for Automotive Medicine Committee on injury scaling. The abbreviated injury scale 1990 revision-update 98. 1980 Revision 1998, Des Plains, IL: American Association for Automotive Medicine, American Association for Automotive Medicine.
38. Wilson JT, Pettigrew LE, Teasdale GM. Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome Scale: guidelines for their use. J Neurotrauma 1998, 15:573-585. 10.1089/neu.1998.15.573, 9726257.
39. Perel P, Arango M, Clayton T, Edwards P, Komolafe E, Poccock S, Roberts I, Shakur H, Steyerberg E, Yutthakasemsunt S. Predicting outcome after traumatic brain injury: practical prognostic models based on large cohort of international patients. BMJ 2008, 336:425-429. 2249681, 18270239.
40. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Muller M. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinforma 2011, 12:77.
41. Scholz M, Cinatl J, Schadel-Hopfner M, Windolf J. Neutrophils and the blood-brain barrier dysfunction after trauma. Med Res Rev 2007, 27:401-416. 10.1002/med.20064, 16758487.
42. Vecil GG, Larsen PH, Corley SM, Herx LM, Besson A, Goodyer CG, Yong VW. Interleukin-1 is a key regulator of matrix metalloproteinase-9 expression in human neurons in culture and following mouse brain trauma in vivo. J Neurosci Res 2000, 61:212-224. 10.1002/1097-4547(20000715)61:2<212::AID-JNR12>3.0.CO;2-9, 10878594.
43. Hyam JA, Welch CA, Harrison DA, Menon DK. Case mix, outcomes and comparison of risk prediction models for admissions to adult, general and specialist critical care units for head injury: a secondary analysis of the ICNARC Case Mix Programme Database. Crit Care 2006, 10(Suppl 2):S2. 10.1186/cc5066, 3226136, 17352796.
44. Rondina C, Videtta W, Petroni G, Lujan S, Schoon P, Mori LB, Matkovich J, Carney N, Chesnut R. Mortality and morbidity from moderate to severe traumatic brain injury in Argentina. J Head Trauma Rehabil 2005, 20:368-376. 10.1097/00001199-200507000-00008, 16030443.
45. Arango-Lasprilla JC, Ketchum JM, Cifu D, Hammond F, Castillo C, Nicholls E, Watanabe T, Lequerica A, Deng X. Predictors of extended rehabilitation length of stay after traumatic brain injury. Arch Phys Med Rehabil 2010, 91:1495-1504. 10.1016/j.apmr.2010.07.010, 20875505.
46. Ghajar J. Traumatic brain injury. Lancet 2000, 356:923-929. 10.1016/S0140-6736(00)02689-1, 11036909.
47. Donkin JJ, Vink R. Mechanisms of cerebral edema in traumatic brain injury: therapeutic developments. Curr Opin Neurol 2010, 23:293-299. 10.1097/WCO.0b013e328337f451, 20168229.